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Abstract
Hypoxia restricts cell proliferation and cell cycle progression at the G1/S interface but at least a subpopulation of carcinoma
cells can escape the restriction. In carcinoma hypoxia may in fact select for cells with enhanced hypoxic survival and
increased aggressiveness. The cellular oxygen sensors HIF proline hydroxylases (PHDs) adapt the cellular functions to
lowered environmental oxygen tension. PHD3 isoform has shown the strongest hypoxic upregulation among the family
members. We detected a strong PHD3 mRNA expression in tumors of head and neck squamous cell carcinoma (HNSCC). The
PHD3 expression associated with expression of hypoxic marker gene. Using siRNA in cell lines derived from HNSCC we show
that specific inhibition of PHD3 expression in carcinoma cells caused reduced cell survival in hypoxia. The loss of PHD3, but
not that of PHD2, led to marked cell number reduction. Although caspase-3 was activated at early hypoxia no induction of
apoptosis was detected. However, hypoxic PHD3 inhibition caused a block in cell cycle progression. Cell population in G1
phase was increased and the population in S phase reduced demonstrating a block in G1 to S transition under PHD3
inhibition. In line with this, the level of hyperphosphorylated retinoblastoma protein Rb was reduced by PHD3 knock-down
in hypoxia. PHD3 loss led to increase in cyclin-dependent kinase inhibitor p27 expression but not that of p21 or p16. The
data demonstrated that increased PHD3 expression under hypoxia enhances cell cycle progression and survival of
carcinoma cells.
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Introduction
Oxygen level in tissues is reduced in many pathological
conditions including cancer progression [1]. Solid tumours
develop areas of poor oxygenation as they outgrow their blood
supply. Mammalian cells have developed an array of mechanisms
in order to adapt to and survive under varying oxygen tensions.
The responses to hypoxia include upregulation of angiogenic
factors and the switch from oxidative to glycolytic metabolism [2].
In cancer cells low oxygen tension induces genetic instability [3,4]
and is a strong driving force in the clonal selection that supports
more aggressive disease.
When cells are exposed to acute hypoxia cell proliferation is
inhibited by several mechanisms such as activation of quiescence,
apoptosis, necrosis and differentiation. In hypoxia also cell cycle is
arrested occuring at the G1/S interface [5,6]. The key molecular
event needed for the G1 to S transition is the hyperpho-
sphorylation of the retinoblastoma protein (Rb) that is performed
by cyclin-dependent kinase (CDK) –cyclin complexes. Hyperpho-
sphorylation of Rb at late G1 releases E2F transcription factor and
allows S-phase to proceed. Under hypoxic conditions Rb is
hypophosphorylated thus inhibiting the transcription of S-phase
genes and cell cycle progression [7,8,9]. Several possible
mechanisms as to how hypoxia may regulate cell cycle progression
have been suggested. Hypoxia has been reported to upregulate
p21(Cip1/Waf1/CDKN1A) and p27(Kip1/CDKN1B) which
regulate the inactivation of cyclin E – CDK2 –complex. While
there is some controversy on the role of p27, the hypoxic cell cycle
arrest does not seem to require p21 [10,11]. Hypoxia may also
activate cell cycle arrest by inhibiting c-Myc transcriptional
activity [12]. Also p16(INK4a) that attenuates cell cycle progres-
sion has been shown to be hypoxia-inducible [13]. Noticeably, a
subpopulation of cancer cells need to escape the hypoxic cell cycle
arrest in order to maintain growth.
Many of the responses to hypoxia are mediated by hypoxia-
inducible transcription factor (HIF) that is rapidly degraded in
normoxia but stabilized under hypoxia [14]. In normoxia the
alpha subunit (HIF-a) is hydroxylated by a family of prolyl
hydroxylase domain containing enzymes (PHDs) [15,16]. Hy-
droxylation of HIF-a allows its recognition by the von Hippel-
Lindau protein and leads to subsequent proteosomal degradation
of HIF-a [17,18,19,20]. PHDs are enzymes that require molecular
oxygen as substrate. Therefore under hypoxic conditions the
activity of PHDs is lowered thus allowing HIF-a to escape
degradation. The stabilized HIF-a is translocated to nucleus where
it dimerizes with HIF-1beta forming an active transcription factor
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regulating cell cycle [21].
In mammals three prolyl hydroxylase isoforms termed PHD1,
PHD2 and PHD3 (also called EGLN2, EGLN, EGLN3,
respectively) have been characterized [22]. All of these isoforms
have been shown to hydroxylate HIF-a in vitro and to have similar
co-factor requirements. The most ubiquitous factor controlling the
activity of these enzymes is oxygen concentration but they also
require 2-oxoglutarate and iron as cofactors. Despite the
similarities in their requirements, several differences in their
function and characteristics exist [23]. Unlike the other two
isoforms, PHD3 has been shown to cause apoptosis in neuronal
cells as well as in cancer cells when expressed under normoxia at
high levels [24,25,26,27]. PHD3 is also the isoform that shows
most robust induction under hypoxia [28,29,30,31]. The elevated
expression is likely to at least partially compensate for the reduced
activity under hypoxia. In fact, PHD3 is known to retain much of
its enzymatic activity at least under moderate hypoxia [32].
Here we have studied the role of PHD3 depletion under
hypoxia in cancer cell lines. We show that PHD3 is upregulated in
squamous cell carcinoma tumours. We show that PHD3 depletion
under hypoxia leads to cell cycle arrest that occurs at the G1/S
boundary. In line with this, the depletion of PHD3 reduces the
amount of hyperphosphorylated retinoblastoma protein as well as
the amount of cyclin D1. Moreover, PHD3 inhibition upregulates
the expression of cyclin-dependent kinase inhibitor p27.
Results
Head and neck squamous cell carcinoma tumors
overexpress PHD3
PHD3 has been reported to be activated by hypoxia in several
cell types including diverse carcinoma cell lines [30,33,34]. In
order to study hypoxic PHD3 expression in human head and neck
squamous cell carcinoma (HNSCC) we used five different primary
cell lines (UT-SCC) established from HNSCC patients at Turku
university hospital [35]. The cells were exposed to normoxia or
hypoxia for 6 and 48 hours. PHD3 was strongly induced at
mRNA level in all cell lines tested with maximal induction seen
after 48-hour hypoxia (Fig. 1A, Fig. S1A,B). In line with this,
PHD3 was induced at protein level in three cell line tested (Fig. 1B).
To study the PHD3 mRNA expression in human HNSCC, we
analyzed tumor samples from 28 HNSCC patients and from
anatomically matching samples in 11 healthy controls. The Q-RT-
PCR analysis showed a 5-fold overexpression of PHD3 (p-
value,0.0001) in the tumor samples as compared to control
(Fig. 1C and D). To investigate whether the PHD3 expression
associates with hypoxia, we analyzed the correlation between
PHD3 and a widely used hypoxic marker glucose transporter
Glut-1. Strong correlation between PHD3 and Glut-1 mRNA
expression was detected (Spearman correlation 0.8, p-val-
ue,0.0001) implying that PHD3 transcription is activated by
hypoxia in HNSCC (Fig. 1D).
To further study the clinical occurrence of PHD3 overexpres-
sion in HNSCC we analyzed studies deposited in the Oncomine
database [36]. From the five studies comparing PHD3 expression
in HNSCC and normal tissue four showed overexpression of
PHD3. In three studies the HNSCC overexpression was
statistically significant (p-value,0,002 to 0,005) (Fig. 1E). More-
over, one study demonstrated increased PHD3 mRNA level in
different anatomical locations including tongue, mouth floor and
tonsilla (Fig. 1F) [37]. PHD3 overexpression was not restricted to
HNSCC (Table S1).
PHD3 inhibition reduces hypoxic SCC growth
As PHD3 was overexpressed in HNSCC we asked whether
PHD3 provided growth advantage for the carcinoma cells. We
used previously validated double stranded PHD3 siRNA (siPHD3)
to knock down the expression of PHD3. As controls non-target
(siScr) and PHD2-targeted siRNA (siPHD2) were used [38]. The
siRNAs were transfected to UT-SCC2 cells followed by exposure
to normoxia (21% O2) or hypoxia (1% O2) for 48 hours. The
PHD3 siRNA was effective and specific as demonstrated by
reduced hypoxic PHD3 expression in SCC2 cells (Fig. 2A, Fig.
S1C).
Noticeably, we detected that the PHD3 knock-down caused a
marked reduction in cell number as compared to controls when
grown under hypoxia (Fig. 2B). Quantification of the cell number
in hypoxia demonstrated almost 70% reduction in surviving cells
after 48-hour hypoxia with siPHD3 as compared to either control
or siPHD2 transfected cells (Fig. 2B and C). In line with the fact
that little PHD3 expression was seen under normoxia, siPHD3
had no marked effect in normoxia.
In order to verify the specific effect of PHD3 siRNA we used a
point-mutated double stranded siRNA (siPHD3mut) as a control.
The mutant siRNA did not affect the PHD3 expression.
Accordingly, siPHD3mut did not have marked effect on the cell
number in hypoxia (Fig. 2E and F) further validating the specific
effect of PHD3 knock-down in reducing the number of surviving
cells under hypoxia.
We further asked whether the reduction in cell number would
be reflected as reduced proliferation rate in siPHD3 cells. PHD3
or control siRNAs were transfected to SCC2 cells followed by
BrdU addition and exposure to normoxia or hypoxia for 48 hours.
Indeed, BrdU incorporation was reduced in siPHD3 cells as
compared to control indicating reduced cell growth under hypoxia
and PHD3 inhibition (Fig. 2D).
Finally, using a rescue experiment we studied whether the
hydroxylase activity of PHD3 was required for supporting hypoxic
cell survival. HeLa cells exposed to siPHD3 were transfected with
PHD3-EGFP, PHD3(R206K)-EGFP (a hydroxylase-inactive mu-
tant) [26] or EGFP as control followed by two day hypoxic
exposure (Fig. 3). The transfection efficiency was controlled with
confocal microscopy for EGFP expression (Fig. S2). Cells
transfected with PHD3-EGFP demonstrated clearly increased
survival as compared to control. Interestingly, PHD3(R206K)-
EGFP displayed comparable enhancement in cell number
suggesting that hydroxylase activity is not required for PHD3
supported cell survival.
Inhibition of PHD3 does not activate significant
apoptosis in SCC cells
As hypoxia is a known inducer of apoptosis we asked whether
the reduction in cell amount was due to enhancement of hypoxia-
induced apoptosis [39]. SCC2 cells were transfected with control
and PHD3 siRNA followed by hypoxia for 6 to 30 hours. The cells
were stained for cleaved caspase-3 which is activated during
apoptosis and widely used as an apoptotic marker. Activation of
caspase-3 was detected in a subpopulation of siPHD3 transfected
cells as compared to control cells after 24-hour hypoxia (Fig. 4A)
while most cells remained caspase-3 negative. Quantification
demonstrated increased activation of caspase-3 by siPHD3 at early
hypoxia (24-h) that was lost at later time points (Fig. 4B).
Caspase-3 activation in a subpopulation of siPHD3 cells could
be suggestive for increased apoptosis. However, the increased
caspase-3 cleavage does not necessarily lead to terminal apoptosis
[40]. Therefore, we next used flow cytometry to further analyze
the occurrence of apoptosis by studying the cell population in sub-
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PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27112Figure 1. PHD3 is overexpressed in human HNSCC and induced by hypoxia. (A) Five different primary human head and neck squamous cell
carcinoma-derived cell lines (SCC) were cultured in normoxia or in hypoxia for 6 and 48 hours. The PHD3 mRNA expression was detected and
quantified by Q-RT-PCR. (B) PHD3 expression in three different SCC cell lines detected by western blot analysis. (C) PHD3 mRNA expression in 28
HNSCC patient tumour samples and in 11 noncancerous anatomically matching samples was determined by Q-RT-PCR and normalized to EF-1a levels
in each sample. Each dot represents the expression in one sample. The median values are indicated by dashed line and numerical value. (D) The
statistical significance of PHD3 mRNA expression in patient and control samples was determined using Spearman correlation and two-tailed
Student’s t-test. The upregulation of PHD3 gene shows statistical significance (p-value,0,0001) and correlates with Glut-1 expression (p-
value,0,0001). (E) Four of five independent head and neck cancer studies extracted from Oncomine database show overexpression of PHD3 in
cancer tissue relative to normal tissue. Three of the studies show statistically significant overexpression of PHD3 in cancer samples compared to
normal tissue. (F) Detailed data analysis extracted from one Oncomine database study [37] for PHD3 expression. The expression is shown in five
anatomically different HNSCC sites relative to control samples.
doi:10.1371/journal.pone.0027112.g001
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PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27112Figure 2. PHD3 is required for SCC cell survival in prolonged hypoxia. (A) PHD3 is induced in hypoxia. Knock-down of PHD3 expression with
siRNA (siPHD3) is specific and does not affect PHD2 or HIF-1a expression. siScr=scrambled control siRNA. (B) SCC2 cells were plated on glass slides,
transfected with siRNAs and exposed to hypoxia for 48 h followed by Hoescht nuclear staining. The samples with PHD3 siRNA showed marked
reduction in cell number in hypoxia. No effects were seen in the normoxic counterparts. (C) Quantification of the cell number in three optical fields
from each sample in three independent experiments. The change in cell number is shown as folds vs. control (siScr). The reduction in cell number of
siPHD3-transfected samples was statistically significant (**; p-value,0,01). (D) The proliferation rate of cells transfected with control (siScr), PHD2 or
PHD3 siRNA was determined using BrdU incorporation. Results from absorbance changes in three independent experiments are shown as folds vs.
control (siScr). (E) To validate the specificity of the effect of PHD3 inhibition on cell survival a point-mutated PHD3 siRNA (siPHD3mut) we used as a
control. siPHD3mut did not affect the viability of SCC cells. (F) Quantification of the cell number in three optical fields. (G) Western blot analysis shows
the effect of the indicated siRNAs on PHD3 expression.
doi:10.1371/journal.pone.0027112.g002
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siRNA and cultured in normoxia and hypoxia for 24 to 72 hours.
As well established, the hypoxic exposure induced apoptosis in
both control and siPHD3 cells. In control cells a 35% induction in
apoptosis rate after 24-hour hypoxia was detected and after
72 hours the apoptosis rate had increased 2-fold (Fig. 4C, Fig. S3).
However, when compared to the normoxic siScr control, the
siPHD3 transfected cells demonstrated similar or even slightly
reduced amount of cell in the sub-G phase (Fig. 4C, Fig. S3).
When compared to siSCr controls at each time point, quantifi-
cation of the apoptotic rate demonstrated small effect of siPHD3
on apoptosis that was insignificant (Fig. 4D). We concluded that
although the exposure of SCC cells to PHD3 inhibition in hypoxia
may activate caspase-3 in a subpopulation of cells this does not
translate to major increase in apoptosis.
PHD3 inhibition enhances hypoxia-induced block in G1
to S transition
As the reduction in cell number could not be explained with
increased apoptosis, we looked for possible defects in the cell cycle
progression. SCC2 cells were transfected with either control or
PHD3-targeted siRNA and incubated in normoxia and in hypoxia
for 24 to 48 hours. Cell cycle was determined using flow cytometer
with propidium iodide staining. As expected, hypoxic exposure led
to an increase in the number of cells in G1 phase and a decrease in
the cell population in S and M phases that peaked after 48-hour
hypoxia indicating a block in G1 to S transition under hypoxia
(Fig. 5A and Fig. S4). Noticeably, siPHD3 transfection led to
further increase in the accumulation of cells in G1 (Fig. 5A and B).
Accordingly, this was accompanied by a decrease in the amount of
cells in the synthesis (S) phase. Quantification of the data from at
least three independent experiments demonstrated constant
increase in the G1 population under hypoxic PHD3 inhibition
(Fig. 5B). Similarly, when compared to normoxic control, an
approximately 10% increase in G1 was seen with PHD3 inhibition
under hypoxia (Fig. S4A). In line with an increase in the G1, a
marked decrease in the S phase with siPHD3 as compared to the
siScr control at each time point was demonstrated under hypoxia
(Fig. 5C, Fig. S4B). The percentual decrease in the S phase by
siPHD3 transfection was approximately 35% and 25% at 24 and
48-hour hypoxia, respectively. Supporting reduced S-phase entry,
a clear reduction of hypoxia-exposed cells in G2/M phase was also
detected (Fig. 5A). The smaller increase in G1 population as
compared to the reduction of S-phase reflects the fact that most
cells at any given time reside in G1 phase. Noticeably, when the
ratio between G1 and S phases was calculated, the difference
between control and PHD3 inhibition was most evident
illustrating a 2-fold increase in hypoxic siPHD3 cells as compared
to control at 24- and 48-hour hypoxia (Fig. 5D). In line with
previous reports on the effect of hypoxia on G1 to S transition, the
difference in G1/S ratio showed 30% and 100% increase by
hypoxia alone at 12- and 24-hours, respectively. This was further
increased to 70% and 170% by siPHD3 exposure (Fig. S4C).
To study whether the siPHD3-induced block in G1 to S
transition was specific for SCC cells we used HeLa cells that were
synchronized and subsequently analyzed by flow cytometry at
shorter timepoints. Hela cells were transfected with PHD3 and
control siRNAs, synchronized with aphidicolin followed by
exposure to hypoxia for 2 to 12 hours (Fig. S5) and calculation
of G1 to S phase ratio. A marked increase in the G1 to S ratio in
siPHD3 cells as compared to either siScr control or siPHD2-
transfected cells was seen (Fig. 5E). The most notable difference
was seen after 12-hour hypoxia when the G1 to S ratio in siPHD3
cells showed a 3-fold increase compared to controls (Fig. 5E).
Together the data demonstrated that in hypoxic carcinoma cells
PHD3 inhibition causes cell cycle arrest at the G1-S border.
PHD3 depletion reduces the amount of
hyperphosphorylated retinoblastoma protein in hypoxia
Hyperphosphorylation of retinoblastoma protein Rb (pRb) is
required for the cell cycle to proceed from G1 to S phase [7,8]. As
we detected a block in the S-phase progression, we next asked
whether the PHD3 inhibition would have an effect on the
phosphorylation status of Rb. SCC2 cells transfected with control
or PHD3 siRNAs followed by hypoxic exposure were analyzed for
phosphorylated Rb at 6 and 48-hour timepoints (Fig. 6A). As
expected, a marked decrease in the amount of pRb in SCC2 cells
was detected under hypoxia as compared to normoxia. Impor-
Figure 3. PHD3 hydroxylase activity is not required for hypoxic cell survival. (A) Cells were exposed to siPHD3, followed by transfection of
the indicated control (EGFP) and PHD3 expressing plasmids (PHD3-EGFP and PHD3R206K-EGFP) and 48 hour incubation in hypoxia. The phase
contrast images show representative examples of cell amount. (A) Quantification of cell number with transfection of indicated plasmids under siPHD3
expression and hypoxia. Means and SD of three visual fields.
doi:10.1371/journal.pone.0027112.g003
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already at 6 hours of hypoxia. At 48 hours the pRb level was
further suppressed in siPHD3 transfected cells (Fig. 6A).
We next analyzed the expression of cyclins B and D. Cyclin D1
forms a complex with cyclin dependent kinases 4 and 6 (CDK4\6)
which phosphorylate Rb and drive the cell cycle. Cyclin D1
expression is elevated during G1 to S transition [41]. Cyclin B1 is a
regulatory subunit of cyclin-dependent kinase 1 (Cdk1) and is
needed for G2 to M phase transition of cell cycle. Cyclin B1
expression serves as a switch for cells to proceed to mitosis. In
accordance with the reduced G1 to S transition, we detected a
decrease in cyclin D1 levels in hypoxic siPHD3-treated cells
(Fig.6A).Alsoa clearreductionincyclinB1expression wasdetected
in cells exposed to hypoxia. The reduction was futher enhanced by
PHD3 depletion (Fig. 6A). PHD3 depletion did not affect the
expression of other cyclins such as cyclin A or cyclin E (not shown).
Figure 4. siPHD3 does not activate marked apoptosis. (A) SCC2 cells transfected with the indicated siRNAs were exposed to hypoxia for 6 to
30 hours. Cells were subsequently stained for caspase-3 (red) and Hoechst nuclear stain (blue). In siPHD3-transfected cells increased activation of
caspase-3 was detected after 24 hour hypoxia. (B) Quantification of caspase-3 activation at the indicated hypoxic time points. Means and SD for five
visual fields are shown. (C) Flow cytometric analysis (FACS) of the sub-G (apoptotic) SCC2 cells. SCC2 cells were transfected with the indicated siRNA
and exposed to 24–48 hours of hypoxia followed by staining with propidium iodide (PI). The amount of cells in sub-G1 was determined. There were
no changes in the size of apoptotic sub-G1 phase population of siPHD3 samples relative to siScr control. (D) Quantification of the apoptotic sub G1
population in SCC2 cells. Three independent experiments are shown as folds vs. control (siScr).
doi:10.1371/journal.pone.0027112.g004
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27112Figure 5. PHD3 inhibition causes a block in G1 to S-phase transition in hypoxia. (A) SCC2 cells were transfected with the indicated siRNAs
and exposed to normoxia (21% O2) or hypoxia (1% O2) for 24 to 48 hours. Samples were and stained with PI and analyzed with FACS. The data was
plotted as cell cycle histograms (FL2-A vs. counts). The cells exposed to PHD3 siRNA showed an increase in the size of G1 population and a decrease
in the S and G2+M populations relative to control. The histograms show representative examples. (B) Quantification of cells in G1 phase after
exposure to the indicated siRNAs and hypoxic treatments. Data from three independent experiments are shown as fold change vs. control (siScr).
Means and SD are shown. (C) Quantification of cells in the S phase after exposure to the indicated siRNAs and hypoxic treatments. Data from three
independent experiments are shown as fold change vs. control (siScr). Means and SD are shown. (D) Calculation of the relative sizes of the G1 to S
phase from three independent experiments. (E) HeLa cells were treated with the indicated siRNAs followed by synchronization of the cells. After
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performed in synchronized HeLa cells (Fig. 6B). In line with the
data from SCC cells, a marked decrease in the amount of pRb in
synchronized siPHD3-treated Hela cells was detected (Fig. 6B). In
HeLa cells a decrease in cyclin D1 levels in siPHD3-treated cells
was evident as well, while hypoxia per se showed little effect on
cyclin D1 level. The suppression of Rb hyperphosphorylation with
reduced expression of cyclins D1 and B1 in cells exposed to
siPHD3 validates the effect of siPHD3 on cell cycle arrest seen in
flow cytometric analyses.
release the cells were exposed to hypoxia for the indicated time. Population sizes of the G1 and S phase cells were determined by FACS and the G1 to
S relation was calculated (arbitrary units).
doi:10.1371/journal.pone.0027112.g005
Figure 6. PHD3 inhibition reduces the amount of hyperphosphorylated Rb and increases p27 in hypoxia. (A) SCC2 cells were
transfected with the indicated siRNAs and exposed to normoxia or hypoxia for 24 to 48 hours followed by western blot analysis of PHD3,
phosphorylated Rb (p-Rb) and cyclin B1. (B) HeLa cells were transfected with the indicated siRNAs, synchronized and exposed to normoxia or hypoxia
for 6 to 24 hours after release. PHD3, phosphorylated Rb (p-Rb) and cyclin D1 were analyzed from samples by western blotting. (C) SCC2 cells were
transfected with the indicated siRNAs and exposed to normoxia or hypoxia for 24 hours followed by western blot analysis of p21(Cip1). (D) Cells
transfected with the indicated siRNAs and exposed to normoxia or hypoxia for 24 hours followed by western blot analysis of p16 and p27. Hypoxia
was monitored by HIF-1a expression. (E) Cells transfected with the indicated siRNAs and exposed to normoxia or hypoxia for 24 and 48 hours
followed by western blot analysis of p27.
doi:10.1371/journal.pone.0027112.g006
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p21(Cip1/CDKN1A) independent. In line with this, the knock-
down of PHD3 did not lead to upregulation of p21 under hypoxia
(Fig. 6C). We further studied the expression of two other cyclin-
dependent kinase inhibitors, p16(INK4a) and p27(Kip1/
CDKN1B) under hypoxic PHD3 inhibition. Similarly to p21,
p16 levels remained unchanged under siPHD3 exposure. In
striking contrast, the inhibition of PHD3 led to clear upregulation
of p27, which is known to arrest cell cycle at G1-phase. This was
evident both in normoxia and hypoxia (Fig. 6D). Interestingly, the
p27 level was reduced by hypoxia at 24 hour time point but
increased at 48 hours as compared to normoxia (Fig. 6E). Taken
together the data indicate that PHD3 is required for cell cycle to
progress from G1 to S-phase under hypoxia and that p27 may
mediate the effect.
Discussion
PHD3 is upregulated by hypoxia and the elevated levels remain
in prolonged hypoxia enabling long-term regulation of hypoxic
cell fate [28,29,30]. Some PHD3 hydroxylation activity is
preserved at least under moderate hypoxia (1% O2) where it has
been suggested to desensitize and prevent excessive HIF-alpha
activity [32,34]. Here we have studied the hypoxic function of
PHD3 in carcinoma cells. First we demonstrated that PHD3 is
elevated in human cancers of the head and neck region. The
increase of PHD3 during carcinogenesis suggested that it may
facilitate tumor progression. Supporting this, the inhibition of
PHD3 expression in cells derived from SCC led to reduced cell
survival under hypoxia. Importantly, we demonstrated that the
inhibition of PHD3 causes cell cycle arrest of carcinoma cells in
hypoxia. The arrest was pinpointed to the G1/S boundary and
was accompanied by a block in Rb hyperphosphorylation as well
as reduced expression of the cyclins D1 and B1. Together the data
suggests that hypoxic upregulation of PHD3 in HNSCC is
necessary for cell survival in hypoxia by allowing cell cycle to
proceed from G1 to S-phase.
Hypoxia is a well-characterized environmental factor that halts
cell cycle and cell proliferation [5,6]. Since energy availability from
oxidative phosphorylation is reduced in hypoxia, it is likely that
cell cycle arrest is to prevent excessive cell death under reduced
oxygen [42]. The hypoxic cell cycle arrest occurs at G1 preventing
cells from proceeding to S-phase where they would be most
susceptible to cell death. In keeping with this, hypoxia is known to
result in Rb hypophosphorylation and reduced cyclin D1
expression [43,44]. However, during the growth of carcinomas a
subpopulation of cells need to escape the cell cycle regulation in
order to maintain cell growth also under low oxygen tension. The
molecular mechanisms that underlie the hypoxia-induced cell
cycle arrest or the mechanisms that can release the arrest in
carcinoma cells are not fully understood. Our work directly links
the primary oxygen sensors to the hypoxic cell cycle arrest as well
as Rb hypophosphorylation and reduced cyclin D1 expression.
Out of the three cyclin-dependent kinase inhibitors studied, p27
was the only one the expression of which displayed changes upon
PHD3 inhibition. p27 has several functions in regulating cell cycle
[45]. Expression of p27 at G1 phase inhibits cyclin E/A – CDK2
blocking the transcription of genes that are required for the G1 to
S transition. In particular under adverse conditions p27 is also
known to inhibit the activation of cyclin D – CDK4 complex and
cause a block in S-phase transition. This is well in line with
reduced cyclin D1 expression and G1 arrest seen by PHD3
inhibition. Therefore, it is feasible that p27 mediates the hypoxic
effects of PHD3 on cell cycle. Whether PHD3 affects the
transcription or protein degradation of p27 remains to be
investigated. Moreover, it is not clear whether the hypoxic block
requires p27 cell cycle inhibitor activity [10,11]. This may be
context-dependent and also vary depending on the length of
hypoxia. Our data indicate that p27 is first suppressed under
hypoxia but reactivated upon longer exposure.
Under hypoxia PHD3 expression is activated by HIF
[28,30,31]. In turn, HIF-a is the main known enzymatic target
of PHD3. Whether the downstream effects of PHD3 on cell
survival are mediated by HIF remain elusive. Given the large body
of evidence that HIF functions as a protective factor for hypoxic
cells it is difficult to see how the knockdown of an HIF inhibitor
PHD3 could cause increased cell death. However, one needs to
keep in mind that PHD3 is likely to fine tune the HIF-a level in
hypoxia where excessive HIF accumulation might shift the cell fate
decision towards cell death. Experimentally it will be challenging
to study the possible HIF-mediated effects on cell cycle under
PHD3 inhibition, as the effect of PHD3 in hypoxia may be to
retain HIF level within a narrow range that can support cell cycle
progression. Reaching such level in a large cell population using
simultaneous HIF and PHD3 inhibition will be challenging.
Supporting the idea that the functions are not mediated by HIF,
the rescue experiments suggested that PHD3 hydroxylase activity
is not required for cell survival supporting function. This is not
completely surprising since a number of hydroxylase activity
independent functions have been ascribed for the PHD family
members [23,46]. Interestingly also, the experiments suggested
that even when only a fraction of the cells express PHD3, this is
reflected in a survival benefit for a larger cell population,
suggesting a bystander effect.
Several studies have indicated that when overexpressed in
normoxia, PHD3 can activate apoptotic cell death in neuronal
cells [24,25,27,47]. Such cell death induced by PHD3 has also
been reported in some carcinoma cells [26,48]. However, similarly
to our work, more recent reports have also indicated that under
hypoxia PHD3 may in fact protect cancer cells from cell death
induced either by hypoxia or other apoptotic factors [49]. This
implies that PHD3 has a dualistic function in regulating cell fate
decisions that depend at least on cell-type and oxygen availability
but probably also on other interacting factors. For example, a
recent study suggests that inhibition of PHD3 in hypoxic
carcinoma cells lacking PRP19 may reduce apoptosis [50]. In
the present study we detected activation of caspase-3 in a
subpopulation of siPHD3 transfected cells under hypoxia. Initially
this could have been interpreted as an increase in the apoptosis
rate. However, it has been well documented that caspase-3
activation does not necessarily lead to terminal apoptosis [40]. In
keeping with this, we were unable to detect any significant increase
of terminal apoptosis in siPHD3-exposed cells by flow cytometry.
It needs to be underlined that these analyses are internally
controlled by reduced S-phase entry. The data strongly argues
against apoptosis as the main cause of reduced cell survival by
PHD3 inhibition in hypoxic squamous carcinoma cells.
PHD1 has recently also been shown to regulate cell cycle
progression and cyclin D1 expression [51]. This was shown in
estrogen-dependent breast carcinomas where loss of PHD1 led to
decrease in cyclin D level and subsequently impaired cell
proliferation. In the current work we focused on the hypoxia-
induced PHD isoforms PHD2 and -3. In glioblastoma cells the
inhibition of either PHD2 or PHD3 was protective against
hypoxia and staurosporine-induced cell death [49]. In SCC cells
however, PHD2 inhibition demonstrated far less cell death or
effects on the cell cycle as compared to PHD3. Together the data
suggests cell-type specific effects of the PHD isoforms on cell
Hypoxic Cell Cycle Arrest by PHD3 Inhibition
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be a feasible mean to block the hypoxia-induced cell survival at
least in squamous cell carcinomas.
Materials and Methods
Patient samples
Tumor samples were collected, after informed written consent,
from surgically removed oral and oropharyngeal HNSCC in
Turku University Hospital, Finland. Normal tissue samples used as
a control were collected from patients undergoing uvulopalato-
pharyngoplasty. Samples were from both genders and the age of
the patients ranged from 29 to 87 years. All procedures in this
study were approved by the National Authority for Medicolegal
Affairs and by the ethics committee of Turku University Hospital.
All data were analyzed anonymously. The patient material has
been described in detail elsewhere [52,53]. For database studies
Oncomine
TM was used [36].
Cell culture and transfections
HeLa cells were obtained from the American Type Culture
Collection, Rockville, MD, USA. The cancer patient-derived
HNSCC cell lines UT-SCC2, UT-SCC7 and UT-SCC9 used in
this study have been at the University of Turku and described
previously [35]. Cells were cultured in DMEM, supplemented
with 10% FCS, penicillin-streptomycin and L-glutamine. The
SCC cells were also supplemented with nonessential amino acids
(Sigma-Aldrich). Cells were cultured in humidified air condition-
ing 5% CO2 at 37uC. For hypoxia treatments air was replaced by
nitrogen to reach 1% oxygen in a hypoxia workstation (Invivo2).
For siRNA experiments, double stranded siRNA oligonucleo-
tides were used at 200 nM final concentration. Transfections were
performed with Oligofectamine (Invitrogen) following the manu-
facturer’s protocol. The siRNAs (MWG Biotechnology) used were:
siPHD2 59-GACGAAAGCCAUGGUUGCUUG (dTdT)-39; siP-
HD3 59-GUCUAAGGCAAUGGUGGCUUG(dTdT)-39; siPH-
D3 off-target 59-GUC UAAGGCAUAGGUGGCUUG(dTdT)-39
and non-target (scr) siRNA 59-CCUACAUCCCGAUCG AU-
GAUG(dTdT)-39.
For some of the cell cycle experiments the cells were
synchronized using aphidicolin at 1 mg/ml. 18 to 22 hours after
incubation the cell cycle was released by washing the cells with
PBS three times and adding fresh media to the cells.
mRNA, western blot analysis and antibodies
RNA was extracted using RNeasy mini kit (Qiagen). Q-RT-
PCR (Taqman) cDNA was prepared with M-MMLV RT (H
2)
(Promega) and NTP-mix (Fermentas) at 0,5 mM and analyzed
according to manufacturer’s instructions (Applied Biosystems).
Taqman primers (Eurogentec) used were: PHD3 fwd 59 – CG-
AAGTGCAGCCCTCTTACG – 39; PHD3 rev 59 – TTT-
TGGCTTCTGCCCTTTCTT – 39 and PHD3 probe (Euro-
gentec) 59 – AACCAGATATGCTATGACTGTCTGGTACTT-
TGATGCT – 39. The expressions were normalized against EF-
1a.
For protein analysis cells were harvested in SDS-Triton lysis
buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% Triton X-
100, 5% glycerol, 1% SDS, 1 mM Na3VO4, 1 mM phenyl-
methylsulphonyl fluoride and 10 mM NaF,). Protein concentra-
tions were measured with Bio-Rad DC protein assay before
addition of 66SDS buffer. Proteins were detected by Western
blotting and enhanced chemiluminescence with specific antibod-
ies: active caspase 3 (G748A, Promega, 1:500), cyclin B1 (sc-752,
Santa Cruz Biotechnology, 1:2000), cyclin D1 (sc-246, Santa Cruz
Biotechnology, 1:2000), HIF-1alpha (610959, BD Transduction
Laboratories, 1:3000), PHD2 (NB 100–137, Novus Biologicals,
1:3000), PHD3 (NB 100–139, Novus Biologicals, 1:2000) and Ac-
74 b-actin antibody (Sigma-Aldrich, 1:4000). Secondary anti-
mouse-HRP and anti-rabbit-HRP (DAKO) antibodies were used
at 1:10 000.
Cell proliferation, imaging and immunocytochemistry
For BrdU proliferation assay the cells were transfected with
corresponding siRNA and plated on 96-well plates (8 wells per
siRNA). Plates were incubated in normoxia or in hypoxia for
48 hours. BrdU was added and incubated for 4 hours. The cell
proliferation was measured with colorimetric ELISA, BrdU assay
(Roche Diagnostics). BrdU assay was performed according to
manufacturer’s instructions.
For cell counting the cell nuclei cells were fixed with PTEMF
fixing solution (100 mM PIPES pH 6.8, 10 mM EGTA, 1 mM
MgCl2, 0,2% Triton X-100 and 4% formaldehyde) and stained
with the nuclear stain Hoechst 33342 (Invitrogen). Optical fields of
cells were imaged with Zeiss Lumar V12 fluorescence stereo
microscope (Carl Zeiss) and the number of nuclei per optical field
was calculated using ImageJ software (NIH, USA) nucleus
calculator option. Experiments were done as parallel treatments
and each experiment was repeated at least three times. For
detection of active caspase 3 the cells were stained with caspase 3
antibody described earlier.
Flow cytometry
Cell cycle and apoptosis were detected with flow cytometer (BD
FACSCalibur, BD Biosciences). The samples were collected by
trypzination, washed and fixed with 70% ethanol in 220uC for
24 h. The fixing solution was removed by centrifugation and
nuclei were washed with PBS. Staining was done in RT with
propidium iodide (PI) (10 mg/ml) in PBS with 0,1% Tween. The
cell cycle histograms were analyzed using BD CellQuest Pro
software (BD Biosciences).
Statistics
For statistical analysis Spearman correlation and two-tailed
Student’s t-test were used.
Supporting Information
Figure S1 Hypoxia induces the expression of PHD2 but
not PHD1 in UT-SCC. Five different primary human head and
neck squamous cell carcinoma-derived cell lines (SCC) were
cultured in normoxia or in hypoxia for 6 and 48 hours. The cells
were exposed to normoxia or hypoxia for 6 and 48 hours. The
PHD mRNA expression was detected and quantified by Q-RT-
PCR. (A) PHD1 mRNA levels reduced during prolonged hypoxic
exposure whereas (B) the PHD2 levels were induced in short
hypoxia. (C) PHD3 mRNA levels under siPHD3 exposure in
normoxia (left-hand panel) and hypoxia (right-hand panel). Please
note the different scale for normoxia and hypoxia.
(TIF)
Figure S2 Expression of transfected EGFP, PHD3-EGFP
and PHD3R206K-EGFP (Fig. 3) studied by confocal
microscopy.
(TIF)
Figure S3 Hypoxia-activated apoptosis is not enhanced
by PHD3 inhibition. The apoptosis rate was determined by
flow cytometer at the indicated time points. The hypoxic exposure
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(siScr) transfected and siPHD3 cells.
(TIF)
Figure S4 PHD3 inhibition causes a block in G1 to S
transition under hypoxia. (A) Quantification of cells in G1
phase after exposure to the indicated siRNAs and hypoxia. The
data from figure 4 is calculated as fold change vs. normoxic
control. Data from three independent experiments with means
and SD are shown. (B) Quantification of cells in S phase after
exposure to the indicated siRNAs and hypoxia. The data from
figure 4 is calculated as fold change vs. normoxic control. Data
from three independent experiments with means and SD are
shown. (C) Hypoxic G1 to S phase block is enhanced by PHD3
inhibition. SCC2 cells were transfected with the indicated siRNAs
and exposed to normoxia (21% O2) or hypoxia (1% O2) for 24 to
48 hours. Samples were and stained with PI and analyzed with
FACS. Calculation of the relative sizes of the G1 to S phase from
three independent experiments. The data are shown as increase
normoxic controls.
(TIF)
Figure S5 The effect of aphidicolin on cell cycle
progression under normoxia and hypoxia. (A) Aphidicolin
causes a cell cycle block which is released immediately after
medium change. The cell cycle was blocked by aphidicolin
treatment for 20 to 22 hours. The cell cycle was released by
washing with PBS and by adding fresh media on the cells. The
progression of the cell cycle was followed by flow cytometry in
normoxia (21% O2) and hypoxia (1% O2). The curves illustrate
the release of cell cycle inhibition (0 h) at S phase over 24 hours.
(B) The effect of aphidicolin and release for G1 phase for normoxia
(21% O2) and hypoxia (1% O2).
(TIF)
Table S1 Selected studies extracted from Oncomine
database investigating PHD3 mRNA expression in
diverse cancers vs. matching normal tissue.
(DOC)
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